Search bioRxiv⌕ Search

Biology subjects

Almeida, J. S. d.

Publications and source records attributed to Almeida, J. S. d..

2 recordsLinked to original sources

Comparative metabolic profile of mice fed a grain-based controlled diet and a purified controlled diet

PurposeGrain-based control diets and purified diets are widely used in metabolic studies involving rodents, although their compositional differences may influence physiological outcomes and experimental interpretations. This study aimed to compare the metabolic profile of C57BL/6 mice fed a grain-based diet or a purified diet, both administered under normocaloric conditions. MethodsMale C57BL/6 mice (7 weeks old) were fed a grain-based diet or a purified diet for 12 weeks. Body mass and composition, fasting blood glucose, oral glucose tolerance, and plasma lipid profile (triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and very low-density lipoprotein cholesterol) were evaluated. Statistical analyses were conducted using an unpaired Students t-test (P [≤] 0.05). ResultsNo significant differences were observed between groups in the evolution of body mass, body composition, fasting blood glucose, oral glucose tolerance, or plasma lipid parameters. ConclusionUnder normocaloric conditions, grain-based or purified control diets produce equivalent metabolic profiles in C57BL/6 mice, supporting their interchangeable use as control diets in metabolic research studies.

physiology↗

Liraglutide exerts protective effects on MASLD independently of lipophagy, and the combination with kombucha presents no additional advantage

Metabolic dysfunction - associated steatotic liver disease (MASLD) has a high global prevalence, requiring effective therapeutic options. This study investigated the effects of liraglutide and kombucha, alone and in combination, in a murine model of high-fat diet (HFD)-induced MASLD. Metabolic parameters, body composition, liver histology, lipid profile, and markers of lipophagy were evaluated. The results demonstrate that liraglutide reduced body weight, fat mass, and lean mass, as well as food and caloric intake, fasting blood glucose, hepatic triglycerides (TG), steatosis, and fibrosis, improved the lipid profile and glucose tolerance, and increased lysosomal acid lipase (LAL) expression in the liver. Kombucha reduced lean mass, liver steatosis, hepatic TG, food and caloric intake, fasting blood glucose, low-density lipoprotein cholesterol (LDL-C), and liver fibrosis, in addition to improving glucose tolerance. However, the combination of treatments did not show synergistic effects superior to those of liraglutide alone. Although liraglutide independently impacted LAL expression, none of the other lipophagy markers were modulated in the liver, suggesting that the beneficial mechanisms of action are independent of the lipophagy pathway. It is concluded that both liraglutide and kombucha are valid strategies for mitigating MASLD, but the combination does not offer superior advantages over liraglutide monotherapy.

molecular biology↗